Focused on molecular liquid biopsy cancer diagnostics since 2014

Wren Laboratories is a CAP and CLIA-certified clinical testing and R&D laboratory established in 2014. The laboratory was founded as a commercial extension of their decades of academic and medical research into non-invasive liquid biopsy tests for a wide variety of cancers and other diseases that can be detected and better understood via molecular biomarkers such as mRNA.

Our Mission

When it comes to managing cancer, knowledge is power.

At Wren Laboratories, our liquid biopsy-based diagnostics use molecular science to uncover precise information about cancer in real time, enhancing pathology and imaging. We help oncologists clarify cancer diagnoses so they can recommend, manage, and monitor treatment better.

Our Values

Focused on Science, Innovation, and Collaboration

Be it blood or saliva, our molecular cancer diagnostics provide actionable disease information in real-time.

Committed to Science

We are committed to scientific discipline and harnessing the benefits of rigorously applied molecular science.

A Pioneering Spirit

To combat cancer effectively, an innovative approach is essential, leveraging cutting-edge applications and techniques.

True Collaborators

We know managing cancer requires inspired teamwork. We are open, connected, and fully collaborative.

Excellence throughout Execution

We seek excellence across all phases of our operations: research, clinical testing, and data analysis.

Focused on Success

The stakes could not be higher in our space; our principal focus is to positively impact the lives of cancer patients.

Company Milestones

History of Wren Laboratories

JUL 2014
L
JUL 2014

Laboratory establishment, Branford, Connecticut.

OCT 2014
L
OCT 2014

Clinical laboratory certification in Connecticut, CLIA license for the NETest.

MAY 2018
L
MAY 2018

California Department of Health Permit - NETest.

AUG 2018
L
AUG 2018

New York State Department of Health Permit – NETest.

OCT 2018
L
OCT 2018

Development of the PPQ – PRRT Predictive Quotient.

NOV 2019
L
NOV 2019

Set-up of NETesting at Sarah Cannon, UK.

AUG 2019
L
AUG 2019

FDA-EUA for nasopharyngeal swab SARS-CoV-2 diagnosis.

OCT 2020
L
OCT 2020

FDA-EUA for COVID-19 PCR saliva testing.

JAN 2021
L
JAN 2021

Development of an at-home saliva collection kit.

DEC 2022
L
DEC 2022

CAP certification.

MAR 2023
L
MAR 2023

Development of the PROSTest – a molecular genomic assay for prostate cancers.

Creators of The NETest

The first commercial offering from Wren Laboratories was the NETest, an in vitro blood-based liquid biopsy that assesses the targeted gene expression profile of mRNA isolated from peripheral blood to diagnose neuroendocrine tumors. Since its availability in October 2014, oncologists have utilized our test over 10,000 times to assist in characterizing neuroendocrine tumors, recommending treatment, and monitoring tumor behavior during recovery.

Credentials & Licenses

CAP #8640840
CLIA # 07D2081388
State of Connecticut Clinical
Laboratory License CL-0996
New York State Department of Health
Clinical Laboratory Permit PFI: 9138
Florida State License 800027786, certificate 101250
Pennsylvania State Laboratory ID: 34347
California State Laboratory ID: COS00800634

About our Lab

Our CAP-accredited and CLIA-certified Clinical Lab

All the molecular research, testing, and analysis we do is conducted at our CAP-accredited and CLIA-certified clinical laboratory in Branford, CT. The College of American Pathologists (CAP) accredits laboratories that meet their standards for quality of services using established performance standards. CLIA, or Clinical Laboratory Improvement Amendments, regulates laboratory testing and requires clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before being able to accept human samples for diagnostic testing.

Most of the liquid biopsy tests we perform are based on real-time quantitative polymerase chain reaction (qPCR) methodology using RNA isolated from peripheral blood or saliva. qPCR is known for sensitive, specific, and reproducible gene expression measurement. Within our lab, we have optimized and standardized the testing processes utilized by our experienced and highly-trained technicians, who adhere to extensive quality control procedures to ensure reproducible and reliable testing results at every stage of our testing process:

RNA quantity and quality:

There must be a sufficient quantity of purified RNA to perform all qPCR reactions. The RNA must also meet acceptance criteria for purity, which includes testing for the presence of excess genomic DNA, which can interfere with gene expression measurement.

Gene-specific measurement ranges:

The measured quantity of each gene product must fall within established ranges.

Efficiency of qPCR:

The output of the polymerase chain reaction process, which doubles the target material every cycle, must fall within defined limits.

Accuracy & Precision:

Accuracy is the degree to which measurements equal the actual quantity in the absence of variability. Precision is the random variation from true quantity. Each of the genes tested must be within established accuracy and precision specifications.

Meet the team

Our Key Personnel

Irvin M. Modlin

Founder, Clinical and Scientific Consultant

Irvin M. Modlin, MD, Ph.D., DSc, an expert in the area of Neuroendocrine Tumor (NET) disease, is the Medical Director of Wren Laboratories and is a Clinical Consultant to the testing laboratory. He is the former director of the Gastrointestinal Pathobiology Research Group and is now an Emeritus Professor at Yale University.

Daniel Buck

General Manager

Daniel Buck, MBA, MPH, joined Wren Laboratories in February 2022 as General Manager, bringing with him over 25 years in the commercial clinical laboratory and pathology industry. Prior to Wren, Dan was CEO of Pathologists Diagnostic Laboratory (PDL) and Pathologists Diagnostic Services (PDS) leading a large, sub-specialized pathology physician practice.

Mark Kidd

Scientific and Laboratory Director

Mark Kidd, Ph.D., DABCC has worked and published extensively in the area of Neuroendocrine Tumor (NET) disease and is the Scientific Director of Wren Laboratories. He is credentialed with the American Board of Clinical Chemistry in Molecular Diagnostics to perform and report on molecular-based diagnostic testing.

Mark L. Harman

Clinical Consultant

Mark Harman, MD, MBA, MS, MCMAS, BCP, has over 15 years of leadership, medical, and research experience. He is a physician executive who brings clinical expertise, business acumen, and scientific innovation to drive organizations to deliver value through solutions that advance medical knowledge, enhance patient care, and support growth across multiple therapeutic areas.

Srinivas Koduru

Director, Transcriptomics

Tracy Auster

Lab Manager

EJ Vongher Professional Headshot

E.J. Vongher

Director, Marketing

Andi Neugarten

Director, Corporate & Business Development

Strategy & Pipeline

Our Scientific Strategy 
and Forward Focus

Our scientific strategy involves identifying a series of gene signatures that enable us to categorize the state of a disease, primarily cancer at this stage. This information can be utilized for timely disease recurrence identification or to assess the effectiveness of therapy.

A key component of the strategy is the development of specific biomathematical algorithms to identify gene-signaling clusters that provide unique information regarding different types of tumor cell proliferation and metastatic potential.

This strategy has facilitated the first identification of circulating neuroendocrine and other tumor cell mRNAs as well as defined the specific transcript signatures of the cells that identify disease undetectable by the current standard of care methodology. These can also be used to delineate the rate of growth, the likelihood of metastasis, and sensitivity to specific targeted therapy.

Beyond neuroendocrine cancer, our scientists have utilized this approach to identify blood-based biomarkers for prostate cancer (with our PROSTest), for predicting tumor response to alternate radiation-based therapies (PPQ for Peptide Receptor Radionuclide therapy for NETs ) as well as utilizing a saliva-based PCR test to identify the virus behind Covid-19.

We are currently developing diagnostics for several other solid tumors, including Breast Cancer, Colon Cancer, Lung Cancer, Melanoma, Myeloma, and Pancreatic Cancer.  In addition, we are developing tests for non-cancerous diseases such as endometriosis.

About the Wren Brand

Brand Origins Reflect the History of and Our Enthusiasm for Our Science

Sir Christopher Wren

Most famous as an architect, Wren was also among the first to draw blood from human veins and helped develop mathematics into a fine art that could be applied to gaining scientific insights.

Our Way is mRNA

While most molecular diagnostics utilize DNA or protein, we’ve always focused on mRNA. It offers a high-resolution view of tumor activity. It’s a proven biomarker, having been used successfully since the late ‘90s. And, when preserved in our proprietary buffer solution, it’s stable.

What Wren Means to Us

Wren embodies the imagination and ingenuity necessary to harness the power of molecular genomics to better understand cancer. We are passionate about how our diagnostics help oncologists know more about and better manage cancer.